Mydecine Innovations

Mydecine Innovations is a Canadian neurotechnology company focused on developing psilocybin-based therapeutics and digital health tools for the treatment of mental health conditions, with a primary emphasis on PTSD and smoking cessation. The company combines clinical-stage psychedelic medicine with a proprietary digital therapy platform designed to support patients throughout the psychedelic treatment journey, from preparation through integration. Mydecine also operates an active biosynthesis program aimed at producing novel psilocybin analogues, allowing the company to explore next-generation compounds with potentially improved efficacy, safety, and patentability. This integrated approach positions Mydecine as more than a pharmaceutical developer, but as a full-stack mental health treatment company bridging pharmacology and digital health.

Headquartered in Edmonton, Alberta, Mydecine is publicly traded on the NEO Exchange under the ticker symbol MYCO, providing the company with access to public capital markets to advance its clinical and research programs. The company has pursued clinical trials investigating psilocybin-assisted therapy for smoking cessation, a therapeutic area with significant unmet need and limited pharmacological options. Their pipeline reflects a strategic focus on conditions where conventional treatments have shown persistent gaps, giving Mydecine a differentiated position within the broader psychedelic medicine sector. The dual advancement of both a drug pipeline and a supporting digital platform reflects an ambition to own multiple points of value across the treatment continuum.

Mydecine represents a meaningful contributor to the evolving neurotech and psychedelic medicine landscape at a time when mental health treatment innovation is drawing significant scientific and investor attention globally. By pairing novel compound development with digital therapeutic infrastructure, the company addresses not only the pharmacological challenge of mental illness but also the structural and experiential challenges of delivering psychedelic-assisted care at scale. Their biosynthesis capabilities further distinguish them by enabling proprietary compound development rather than relying solely on naturally derived psilocybin. As regulatory frameworks around psychedelic medicine continue to mature, companies like Mydecine are helping define what the next generation of mental health treatment infrastructure will look like.